AU2019336943A1 - Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof - Google Patents

Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof Download PDF

Info

Publication number
AU2019336943A1
AU2019336943A1 AU2019336943A AU2019336943A AU2019336943A1 AU 2019336943 A1 AU2019336943 A1 AU 2019336943A1 AU 2019336943 A AU2019336943 A AU 2019336943A AU 2019336943 A AU2019336943 A AU 2019336943A AU 2019336943 A1 AU2019336943 A1 AU 2019336943A1
Authority
AU
Australia
Prior art keywords
cyclodextrin
formula
composition
day
thione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019336943A
Other languages
English (en)
Inventor
Natascha AUDOORE
El Mustapha Belgsir
Ine DE COCK
Aswin DEREYMAKER
Anne-Gaëlle FOURNIAL
Nicolas Pineau
Frédéric TURPIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Op2 Drugs
Original Assignee
Op2 Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Op2 Drugs filed Critical Op2 Drugs
Publication of AU2019336943A1 publication Critical patent/AU2019336943A1/en
Priority to AU2025204144A priority Critical patent/AU2025204144A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019336943A 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof Abandoned AU2019336943A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204144A AU2025204144A1 (en) 2018-09-06 2025-06-03 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862727691P 2018-09-06 2018-09-06
EP18306172 2018-09-06
EP18306172.0 2018-09-06
US62/727,691 2018-09-06
PCT/EP2019/073873 WO2020049166A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204144A Division AU2025204144A1 (en) 2018-09-06 2025-06-03 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Publications (1)

Publication Number Publication Date
AU2019336943A1 true AU2019336943A1 (en) 2021-03-18

Family

ID=67841092

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019336943A Abandoned AU2019336943A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
AU2025204144A Pending AU2025204144A1 (en) 2018-09-06 2025-06-03 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204144A Pending AU2025204144A1 (en) 2018-09-06 2025-06-03 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Country Status (11)

Country Link
US (1) US12295969B2 (https=)
EP (1) EP3846856A1 (https=)
JP (1) JP7362725B2 (https=)
KR (1) KR20210054540A (https=)
CN (1) CN113038969A (https=)
AU (2) AU2019336943A1 (https=)
BR (1) BR112021003997A2 (https=)
CA (1) CA3111886A1 (https=)
IL (1) IL281161B2 (https=)
MX (1) MX2021002611A (https=)
WO (1) WO2020049166A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123038A1 (en) * 2020-12-10 2022-06-16 OP2 Drugs Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757B (zh) * 2022-11-24 2024-03-29 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2222133C (en) 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1771938A (zh) 2004-11-09 2006-05-17 胡才忠 茴三硫脂质体及其制备方法
JP6876047B2 (ja) * 2015-09-08 2021-05-26 オーピーツー ドラッグス ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物
BR112018004518A2 (pt) * 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
AU2018232799B2 (en) * 2017-03-07 2021-11-25 Centre Hospitalier Universitaire De Bordeaux Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Also Published As

Publication number Publication date
JP2021536472A (ja) 2021-12-27
IL281161B2 (en) 2024-01-01
KR20210054540A (ko) 2021-05-13
IL281161B1 (en) 2023-09-01
US20210308173A1 (en) 2021-10-07
BR112021003997A2 (pt) 2021-05-25
MX2021002611A (es) 2021-07-21
CA3111886A1 (en) 2020-03-12
IL281161A (en) 2021-04-29
CN113038969A (zh) 2021-06-25
AU2025204144A1 (en) 2025-06-26
EP3846856A1 (en) 2021-07-14
US12295969B2 (en) 2025-05-13
JP7362725B2 (ja) 2023-10-17
WO2020049166A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US12295969B2 (en) Pharmaceutical composition comprising cyclodextrin complexes of anethole trithione or derivatives thereof
JP2019006834A (ja) 毒性アルデヒド関連疾患および処置
AU2018232799B2 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
KR20180049019A (ko) 미토콘드리아의 반응성 산소 종 (ros) 생성과 관련된 질환 치료용 화합물
US9308214B2 (en) Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
JP2016536350A (ja) キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
WO2018162581A1 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
JP6377620B2 (ja) グルコース取り込みを改善するための組成物および方法
CA3005527C (fr) Mirabegron pour le traitement de maladies retiniennes
WO2020067055A1 (ja) 抗神経変性疾患剤
US20130203843A1 (en) Mild cationic mitochondrial uncouplers
FR2827772A1 (fr) Utilisation de derives de thiazoles pour preparer un medicament destine a proteger les mitochondries
RU2775597C2 (ru) Ингибитор продукции реактивных форм кислорода для лечения заболеваний, связанных со свободными радикалами кислорода
RU2527519C2 (ru) Мягкие катионные митохондриальные разобщители
JPH08506096A (ja) カルシウムチャンネル阻害剤および酸化防止剤を用いた虚血症の治療
JPH1192381A (ja) 心不全の予防・治療剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted